LINC00941: A Drug Target / Disease Biomarker (G100287314)

Target Name: LINC00941

NCBI ID: G100287314

LINC00941

Other Name(s): long intergenic non-protein coding RNA 941 | Long intergenic non-protein coding RNA 941 | lncRNA-MUF | RP11-77I22.3

LINC00941: A Drug Target / Disease Biomarker

LINC00941 is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. Its function is not well understood, but it is known to play a role in the development and maintenance of tissues, including the nervous system.

One of the most promising aspects of LINC00941 is its potential as a drug target. LINC00941 has been shown to interact with a variety of molecules, including G protein-coupled receptors (GPCRs), which are a family of transmembrane proteins that play a role in signaling throughout the body.

GPCRs are a common target for drug development because they are involved in a wide range of physiological processes, including sensory perception, neurotransmission, and cellular signaling. By targeting GPCRs, drugs can modulate their activity and have a therapeutic effect on a variety of diseases.

LINC00941 has been shown to interact with multiple GPCRs, including GPCR-C伪2, GPCR-尾2, and GPCR-纬2. These interactions suggest that LINC00941 may have a role in the regulation of GPCR signaling, which could make it a potential drug target.

In addition to its potential role in GPCR signaling, LINC00941 has also been shown to play a role in the regulation of cellular signaling pathways that are involved in the development and maintenance of tissues. For example, LINC00941 has been shown to interact with the protein p180, which is a negative regulator of the T-cell receptor signaling pathway.

The T-cell receptor is a critical molecule that plays a role in the immune system, and its activity is regulated by a variety of factors, including LINC00941. The interaction between LINC00941 and p180 suggests that LINC00941 may have a role in the regulation of T-cell receptor signaling, which could make it a potential drug target for autoimmune diseases.

Another potential application of LINC00941 as a drug target is its role in the regulation of cell proliferation. LINC00941 has been shown to interact with the protein kinase Akt, which is involved in the regulation of cell growth and survival.

The regulation of cell proliferation is a critical process that is involved in the development and maintenance of tissues, and dysregulation of cell proliferation has been implicated in a wide range of diseases, including cancer. The interaction between LINC00941 and Akt suggests that LINC00941 may have a role in the regulation of cell proliferation, which could make it a potential drug target for cancer.

In conclusion, LINC00941 is a protein that has been shown to interact with multiple molecules, including GPCRs, p180, and Akt. These interactions suggest that LINC00941 may have a role in the regulation of cellular signaling pathways that are involved in the development and maintenance of tissues, as well as the regulation of GPCR and Akt signaling pathways. As a result, LINC00941 is a promising candidate for drug development as a potential therapeutic agent for a variety of diseases.

Protein Name: Long Intergenic Non-protein Coding RNA 941

The "LINC00941 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00941 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets